TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Google Secures Pentagon AI Deal for Classified Projects 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
NEWARK, Calif., Feb. 03, 2016 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the following healthcare conferences during the month of February.
LEERINK Partners 5th Annual Global Healthcare Conference
Date: Wednesday, February 10, 2016
Time: 11:55 a.m. EST
Location: New York, New York
2016 RBC Capital Markets’ Global Healthcare Conference
Date: Wednesday, February 24, 2016
Time: 11:00 a.m. EST
Location: New York, New York
These presentations will be webcast and can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcasts will be archived for 30 days.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com
Investor Contact: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
